评估英国前列腺癌风险检查器是否有助于或阻碍前列腺特异性抗原检测政策:一项混合方法研究
Natalia Norori1, Chiara de Biase2, Yui Hang Wong2
1Prostate Cancer UK, London, UK Natalia.Norori@prostatecanceruk.org.
BJGP open
|February 29, 2024
概括
英国前列腺癌风险检查器帮助男性在前列腺癌查方面做出明智的选择. 该工具使大多数用户能够了解PSA测试的风险和好处,支持知情决策.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 公共卫生 公共卫生
- 医疗信息学 医疗信息学
背景情况:
- 英国的前列腺癌检测政策为50岁以上的男性提供免费的前列腺特异抗原 (PSA) 血液检测,旨在提供知情的选择.
- 由于这种政策,PSA测试率的变化可能会加剧健康不平等.
研究的目的:
- 评估前列腺癌英国的风险检查器是否有助于风险男性在PSA测试方面做出明智的决定.
- 评估该工具在支持前列腺癌查的知情选择方面的有效性.
主要方法:
- 在英国进行的一项混合方法研究.
- 通过调查,重点小组和采访,参与了1181名处于危险的男性,伴侣和临床专家.
- 通过社会人口统计和一般实践服务监测数据分析了风险检查器的完成数据.
主要成果:
- 大多数男性 (75.7%) 认为风险检查器使他们能够做出明智的选择.
- 大多数使用者 (79.6%) 至少有一个前列腺癌风险因素被该工具识别出来.
- 与风险检查器的平均交互时间为9分28秒.
结论:
- 在线决策工具,如风险检查器,在吸引高风险男性方面是有效的.
- 这些工具可以成功地支持男性做出关于前列腺癌查 (PSA测试) 的明智决策.
更多相关视频
05:49Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
6.6K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.6K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
